In some people treated with the thyroid medication propylthiouracil, the immune system mistakenly attacks small blood vessels and red blood cells, leading to kidney failure, pancreas inflammation, and anemia—even after stopping the drug. This is rare but can be life-threatening.
Claim Context
Propylthiouracil use in patients with Graves' disease is associated with the development of anti-proteinase 3 (PR3)-positive ANCA vasculitis, which may present with multi-organ involvement including acute kidney injury, pancreatitis, and cold agglutinin disease, even after drug discontinuation, highlighting a rare but severe immune-mediated toxicity.
“We report a rare and complex case of c-ANCA positive vasculitis after PTU therapy complicated with CAD and multisystem organ dysfunction.”
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether PTU use increases the relative risk of PR3-ANCA vasculitis and cold agglutinin disease compared to other antithyroid drugs across multiple populations, adjusting for confounders like duration of therapy and age.
A systematic review and meta-analysis of all published cohort and case-control studies comparing incidence of PR3-ANCA vasculitis and cold agglutinin disease in adults with Graves' disease treated with PTU versus methimazole or radioactive iodine, with standardized diagnostic criteria, minimum 1-year follow-up, and adjustment for age, sex, and treatment duration.
Whether initiating PTU versus methimazole in newly diagnosed Graves' disease patients leads to a higher incidence of PR3-ANCA seroconversion or clinical vasculitis over 24 months.
A double-blind, multicenter RCT of 1,500 adults aged 18–65 with newly diagnosed Graves' disease, randomized to PTU (50–100 mg/day) or methimazole (10–30 mg/day) for 24 months, with monthly ANCA testing, renal and pancreatic function monitoring, and adjudicated diagnosis of vasculitis or CAD by independent reviewers.
The incidence rate of PR3-ANCA vasculitis and cold agglutinin disease among patients on long-term PTU therapy compared to those on methimazole in a real-world clinical setting.
A prospective cohort study following 10,000 adults with Graves' disease treated with PTU or methimazole for at least 12 months, with quarterly ANCA testing, clinical assessments for vasculitis symptoms, and adjudicated diagnosis of CAD or organ failure by standardized criteria.
Whether prior PTU exposure is more common in patients diagnosed with PR3-ANCA vasculitis and cold agglutinin disease than in matched controls without these conditions.
A multicenter case-control study comparing 100 patients with confirmed PR3-ANCA vasculitis and cold agglutinin disease to 300 matched controls without autoimmune vasculitis, assessing prior PTU exposure duration, dose, and timing relative to symptom onset.
That PR3-ANCA vasculitis and cold agglutinin disease can occur in the same individual following PTU use, documenting clinical presentation and response to therapy.
A detailed clinical case report of a patient with Graves' disease on PTU who develops PR3-ANCA vasculitis and cold agglutinin disease, including timing of drug exposure, serologic markers, organ involvement, and response to withdrawal and immunosuppression.